{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:20:12Z","timestamp":1790778012145,"version":"4.1.0"},"reference-count":24,"publisher":"Society of Nuclear Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.2967\/jnumed.121.262368","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T17:54:40Z","timestamp":1631210080000},"page":"899-905","source":"Crossref","is-referenced-by-count":66,"title":["<sup>18<\/sup>F-BMS986192 PET Imaging of PD-L1 in Metastatic Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors: A Pilot Study"],"prefix":"10.2967","volume":"63","author":[{"given":"Pieter H.","family":"Nienhuis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00eas F.","family":"Antunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andor W.J.M.","family":"Glaudemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Jalving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Noordzij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riemer H.J.A.","family":"Slart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik F.J.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geke A.P.","family":"Hospers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2021,9,9]]},"reference":[{"key":"2025012107351097000_63.6.899.1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jamaoncol.2018.4514","article-title":"survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial","volume":"5","author":"Ascierto","year":"2019","journal-title":"JAMA Oncol."},{"key":"2025012107351097000_63.6.899.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082"},{"key":"2025012107351097000_63.6.899.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.0105"},{"key":"2025012107351097000_63.6.899.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70076-8"},{"key":"2025012107351097000_63.6.899.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31601-X"},{"key":"2025012107351097000_63.6.899.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30231-0"},{"key":"2025012107351097000_63.6.899.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104621"},{"key":"2025012107351097000_63.6.899.8","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30700-9"},{"key":"2025012107351097000_63.6.899.9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1624"},{"key":"2025012107351097000_63.6.899.10","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3390\/cancers12051176","article-title":"Surgery for unresectable stage IIIC and IV melanoma in the era of new systemic therapy","volume":"12","author":"Blankenstein","year":"2020","journal-title":"Cancers (Basel)."},{"key":"2025012107351097000_63.6.899.11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/B978-0-12-811161-1.00006-2","article-title":"Brain metastasis: clinical manifestations, symptom management, and palliative care","volume":"149","author":"Noh","year":"2018","journal-title":"Handb Clin Neurol."},{"key":"2025012107351097000_63.6.899.12","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/DAD.0000000000001856","article-title":"Value of PD-L1, PD-1, and CTLA-4 expression in the clinical practice as predictors of response to nivolumab and ipilimumab in monotherapy in patients with advanced stage melanoma","volume":"43","author":"Santos-Briz","year":"2021","journal-title":"Am J Dermatopathol."},{"key":"2025012107351097000_63.6.899.13","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1038\/s41467-018-07131-y","article-title":"Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer","volume":"9","author":"Niemeijer","year":"2018","journal-title":"Nat Commun."},{"key":"2025012107351097000_63.6.899.14","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","article-title":"89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer","volume":"24","author":"Bensch","year":"2018","journal-title":"Nat Med."},{"key":"2025012107351097000_63.6.899.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025012107351097000_63.6.899.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.199596"},{"key":"2025012107351097000_63.6.899.17","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s00259-017-3853-7","article-title":"EANM\/EARL FDG-PET\/CT accreditation - summary results from the first 200 accredited imaging systems","volume":"45","author":"Kaalep","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025012107351097000_63.6.899.18","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2961-x"},{"key":"2025012107351097000_63.6.899.19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13550-016-0174-y","article-title":"An investigation of the relation between tumor-to-liver ratio (TLR) and tumor-to-blood standard uptake ratio (SUR) in oncological FDG PET","volume":"6","author":"Hofheinz","year":"2016","journal-title":"EJNMMI Res."},{"key":"2025012107351097000_63.6.899.20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40644-019-0281-x","article-title":"IRECIST: how to do it","volume":"20","author":"Persigehl","year":"2020","journal-title":"Cancer Imaging."},{"key":"2025012107351097000_63.6.899.21","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-018-0232-4"},{"key":"2025012107351097000_63.6.899.22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0104"},{"key":"2025012107351097000_63.6.899.23","doi-asserted-by":"crossref","first-page":"e1475874","DOI":"10.1080\/2162402X.2018.1475874","article-title":"High expression of PD-1 and PD-L1 in ocular adnexal sebaceous carcinoma","volume":"7","author":"Kandl","year":"2018","journal-title":"Oncoimmunology."},{"key":"2025012107351097000_63.6.899.24","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.241364"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.121.262368","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T16:03:28Z","timestamp":1737475408000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.121.262368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,9]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,1]]},"published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.2967\/jnumed.121.262368"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.121.262368","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,9]]}}}